Medical Market Report

Global Oral Antidiabetic Agents Market By Type (Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, and Alpha-glucosidase Inhibitors), By Application (Home Use, Medical Institutions, and Others), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 137034
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on Oral Antidiabetic Agents Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global oral antidiabetic agents market is segmented on the Type, Application, and geography.

    The worldwide market for Oral Antidiabetic Agents Market is expected to grow at a CAGR of roughly x.x% over the next nine years, and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.

    Oral Antidiabetic Agents Market Scope:

    By type, the market is segmented into Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, and Alpha-glucosidase Inhibitors. By Application, the market is divided into Home Use, Medical Institutions, and Others.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, AstraZeneca, Wockhardt UK, Merck, Pfizer, and Cipla.

    Key Market Segments

    Type

    Sulfonylureas

    Meglitinides

    Biguanides

    Thiazolidinediones

    Alpha-glucosidase Inhibitors

    Application

    Home Use

    Medical Institutions

    Others

    Key Market Players included in the report:

    Novo Nordisk

    Eli Lilly

    Sanofi

    Roche

    Teva

    AstraZeneca

    Wockhardt UK

    Merck

    Pfizer

    Cipla

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Oral Antidiabetic Agents Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Oral Antidiabetic Agents Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Oral Antidiabetic Agents Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Oral Antidiabetic Agents Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Oral Antidiabetic Agents Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Oral Antidiabetic Agents Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Oral Antidiabetic Agents sub-markets, depending on key regions (various vital states).
    To analyze Oral Antidiabetic Agents Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Oral Antidiabetic Agents Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2014 to 2019, and also prediction to 2028.
    Primary worldwide Oral Antidiabetic Agents Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Oral Antidiabetic Agents Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global Oral Antidiabetic Agents Market Overview
    

    3.1. Oral Antidiabetic Agents Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global Oral Antidiabetic Agents Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Oral Antidiabetic Agents Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Sulfonylureas
    

      4.4.
    

      4.5. Meglitinides
    

      4.6.
    

      4.7. Biguanides
    

      4.8.
    

      4.9. Thiazolidinediones
    

      4.10.
    

      4.11. Alpha-glucosidase Inhibitors5. Global Oral Antidiabetic Agents Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Oral Antidiabetic Agents Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Home Use
    

      5.4.
    

      5.5. Medical Institutions
    

      5.6.
    

      5.7. Others6. Global Oral Antidiabetic Agents Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Oral Antidiabetic Agents Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Oral Antidiabetic Agents Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Oral Antidiabetic Agents Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Oral Antidiabetic Agents Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Oral Antidiabetic Agents Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global Oral Antidiabetic Agents Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Novo Nordisk
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4.
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Eli Lilly
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6.
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Sanofi
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8.
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Roche
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10.
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Teva
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12.
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments  7.13. AstraZeneca
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments  7.14.
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments  7.15. Wockhardt UK
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments  7.16.
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments  7.17. Merck
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments  7.18.
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments  7.19. Pfizer
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments  7.20.
    

        7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments  7.21. Cipla
    

        7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.